MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function
Status:
Withdrawn
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study is for patients with cirrhosis and hepatic encephalopathy who are in the hospital.
This means they have a high ammonia level which is affecting their brain function.
All patients will receive the standard of (regular) care. Each will have an equal chance
(like flipping a coin) of receiving the experimental drug or placebo along with the standard
care.
Each patient will have tests during the first 24 hours, receive treatment for up to 5 days,
and have 30 days of follow-up.